论文部分内容阅读
目的:评价桂哌齐特联合厄贝沙坦治疗早期糖尿病肾病的临床疗效。方法:选择糖尿病合并早期糖尿病肾病住院病例60例,随机分为两组,每组30例。A组给予厄贝沙坦治疗,B组在厄贝沙坦治疗的基础上加用马来酸桂哌齐特治疗,疗程14 d,观察治疗前后的24 h尿微量白蛋白(24hUmAlb)和C反应蛋白(CRP)的变化。结果:两组治疗后24hUmAlb均较治疗前下降(A组P<0.05,B组P<0.01),B组下降幅度较A组更大;两组治疗前CRP均高于正常,A组治疗前后CRP无明显变化(P>0.05),B组治疗后CRP水平较治疗前明显下降(P<0.01)。结论:桂哌齐特联合厄贝沙坦治2型糖尿病合并早期糖尿病肾病疗效显著,可以改善血管内皮功能,减少24hUmAlb。
Objective: To evaluate the clinical efficacy of Cinepazide combined with irbesartan in the treatment of early diabetic nephropathy. Methods: Sixty patients with diabetic nephropathy with early diabetic nephropathy were randomly divided into two groups (n = 30 in each group). Group A was treated with irbesartan, group B was treated with irbesartan plus cinepazide maleate for 14 days, 24 hours urine microalbuminuria (24hUmAlb) and C Changes in reactive protein (CRP). Results: The levels of UUAb in 24 hours after treatment in both groups were significantly lower than those before treatment (P <0.05 in group A, P <0.01 in group B), and the decrease in group B was greater than that in group A There was no significant change in CRP (P> 0.05). The CRP level in group B after treatment was significantly lower than that before treatment (P <0.01). Conclusion: Cinepazide combined with irbesartan in type 2 diabetic patients with early diabetic nephropathy significantly improved the vascular endothelial function and decreased 24hUmAlb.2.